Aktieanalys

Scandinavian ChemoTech Q4 2023: Initial take - Redeye

Redeye Publicerad: 05 Mar 09:34

Redeye provides its initial comments on the Q4 2023 report from Scandinavian Chemotech. Sales was lower than we had foreseen, and OPEX was higher. We are encouraged to see the progress that has been made recently, including a positive alteration to the study design at AIIMS Jodhpur and the continued installation of devices in the US market. The cash balance was SEK0.9m at year-end.

Länk till analysen i sin helhet: https://www.redeye.se/research/988387/scandinavian-chemotech-q4-2023-initial-take?utm_source=finwire&utm_medium=RSS

Nyheter om ChemoTech

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!